Atai Life Sciences spotlights early depression data for psychedelic ahead of big readout
2024-03-27
临床2期临床结果
Less than two months after betting $50 million on Beckley Psytech’s psychedelic drugs, atai Life Sciences has shared initial Phase 2a results for one candidate that it says support its use in treatment-resistant depression.
In an open-label study involving 12 patients — 11 of whom were included for analysis — a single dose of Beckley Psytech’s BPL-003 had an antidepressant response on day 2, as measured by the Montgomery–Åsberg Depression Rating Scale. At week 4, 55% of patients were in remission, and 45% were still in remission at week 12, according to atai.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。